BFRI vs. GRAY, ATHE, ERNA, UPC, VIRI, GHSI, GRTX, AEZS, EFTR, and NCNA
Should you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include Graybug Vision (GRAY), Alterity Therapeutics (ATHE), Eterna Therapeutics (ERNA), Universe Pharmaceuticals (UPC), Virios Therapeutics (VIRI), Guardion Health Sciences (GHSI), Galera Therapeutics (GRTX), Aeterna Zentaris (AEZS), eFFECTOR Therapeutics (EFTR), and NuCana (NCNA). These companies are all part of the "pharmaceutical preparations" industry.
Graybug Vision (NASDAQ:GRAY) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
Biofrontera has higher revenue and earnings than Graybug Vision. Graybug Vision is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
Graybug Vision received 10 more outperform votes than Biofrontera when rated by MarketBeat users. However, 60.00% of users gave Biofrontera an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote.
Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.
Graybug Vision has a net margin of 0.00% compared to Graybug Vision's net margin of -59.09%. Biofrontera's return on equity of -77.61% beat Graybug Vision's return on equity.
49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 7.9% of Graybug Vision shares are held by insiders. Comparatively, 0.2% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Biofrontera's average media sentiment score of 0.00 equaled Graybug Vision'saverage media sentiment score.
Biofrontera has a consensus price target of $18.00, indicating a potential upside of 1,068.83%. Given Graybug Vision's higher probable upside, analysts plainly believe Biofrontera is more favorable than Graybug Vision.
Summary
Graybug Vision and Biofrontera tied by winning 7 of the 14 factors compared between the two stocks.
Get Biofrontera News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biofrontera Competitors List
Related Companies and Tools
